Abstract:
The successes of the Human Genome Project catalyzed the transition of genomics from the laboratory to the clinic. Over the past decade, there has been a proliferation of studies demonstrating the potential utility of various applications of genomics as a conduit to accelerate drug development, understand mechanism(s) of action, and personalize treatment. For patients with cancer, genomics-informed medicine has largely focused on issues associated with patients’ malignancies. But with the recognition that genomics is also a pivotal contributor to risk of regimen-related toxicities and how patients respond to treatment, the chances for applying genomics to comprehensive cancer care are increasing.